Mylan NV (NASDAQ:MYL) has been given a consensus recommendation of “Buy” by the twenty-two brokerages that are covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, eight have issued a hold recommendation and eleven have issued a buy recommendation on the company. The average 12 month price target among brokerages that have issued ratings on the stock in the last year is $27.59.
A number of analysts have recently issued reports on the company. ValuEngine upgraded Mylan from a “strong sell” rating to a “sell” rating in a report on Wednesday, October 2nd. SunTrust Banks increased their target price on shares of Mylan from $25.00 to $27.00 and gave the stock a “buy” rating in a research report on Thursday, September 12th. Cfra raised Mylan to a “hold” rating in a research report on Wednesday, November 27th. BidaskClub raised Mylan from a “sell” rating to a “hold” rating in a research report on Thursday, November 28th. Finally, Morgan Stanley downgraded Mylan from an “overweight” rating to an “equal” rating and decreased their target price for the stock from $25.00 to $18.00 in a research report on Thursday, November 7th.
In other news, insider Goulds Bruce 8,000,000 shares of the stock in a transaction that occurred on Friday, November 8th. 0.81% of the stock is owned by corporate insiders.
Shares of MYL traded down $0.03 during trading hours on Tuesday, hitting $19.65. 131,034 shares of the company were exchanged, compared to its average volume of 5,586,987. The company has a market capitalization of $9.71 billion, a PE ratio of 4.31, a PEG ratio of 1.01 and a beta of 1.71. The company has a debt-to-equity ratio of 1.17, a current ratio of 1.43 and a quick ratio of 0.84. The firm has a fifty day simple moving average of $18.40 and a 200-day simple moving average of $18.85. Mylan has a one year low of $16.63 and a one year high of $32.23.
Mylan (NASDAQ:MYL) last released its earnings results on Tuesday, November 5th. The company reported $1.17 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.14 by $0.03. The company had revenue of $2.96 billion during the quarter, compared to analyst estimates of $3.01 billion. Mylan had a return on equity of 18.80% and a net margin of 0.42%. The company’s revenue for the quarter was up 3.5% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.25 earnings per share. Sell-side analysts expect that Mylan will post 4.31 EPS for the current year.
Mylan N.V., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, branded-generic, brand-name, and over-the-counter (OTC) pharmaceutical products in North America, Europe, and internationally. It offers active pharmaceutical ingredients and finished dosage forms; and antiretroviral medicines to treat HIV/AIDS.
Receive News & Ratings for Mylan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan and related companies with MarketBeat.com's FREE daily email newsletter.